Remodulin is an intravenous drug designed to treat pulmonary hypertension. It is owned by United Therap and contains the active ingredient treprostinil. The drug was first authorized for market use on 21 May, 2002 and is available in injectable;iv (infusion), subcutaneous dosage forms.
The generic release of Remodulin is anticipated after the last patent expires, which is projected to be on 29 March, 2029. It's pertinent to mention that patent expirations can sometimes lead to the release of generic versions, though it is not always guaranteed.
Remodulin is used for the treatment of pulmonary hypertension in humans. Its effective administration can be managed in several ways, including diluting it for intravenous infusion with sterile diluent for Flolan or sterile diluent for Epoprostenol Sodium prior to administration. It can also be diluted for infusion with sterile water for injection or 0.9% sodium chloride injection. The drug works due to its active ingredient, treprostinil, or a pharmaceutically acceptable salt thereof, which comprises 0.1 to 5% w/v of the formulation.
Remodulin is covered by a total of 10 patents with none yet expired. The last patent is expected to expire on 29 March, 2029. This might enable the creation of a Remodulin generic. Below are details of the patent: